Indeed, in multiple renal cell carcinoma (RCC) tumor models, the PERK inhibitor HC-5404 was reported to significantly enhance the antiangiogenic effect of standard VEGF receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as axitinib and lenvatinib, inhibiting the formation of both new and mature tumor blood vessels [142]. Here, EIF2AK3 is linked to neoplasm.